Article Information
History
- December 31, 2022.
Article Versions
- You are currently viewing Version 1 of this article (December 31, 2022 - 10:31).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Shujie Si1,*,
- Canrui Jin2,*,
- Yunlong Cao3,4,*,
- Jianping Li2,
- Biao Kan5,
- Feng Xue6,
- Xiaoliang Sunney Xie3,4,
- Liang Fang2,
- Gang Zeng2,
- Shuo Zhang7,†,
- Yaling Hu6,† and
- Xiaoping Dong5,8,9,10,†
- 1Pharmacy department, Inner Mongolia Fourth Hospital, Hohhot, P. R. China
- 2Clinical research and development department, Sinovac Biotech Co., Ltd., Beijing, P. R. China
- 3Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China
- 4Changping Laboratory, Beijing, P. R. China
- 5State Key Laboratory for Infectious Disease Prevention and Control, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
- 6Research and development department, Sinovac Life Sciences Co., Ltd., Beijing, P. R. China
- 7Inner Mongolia Blood Center, Hohhot, P. R. China
- 8Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
- 9China Academy of Chinese Medical Sciences, Beijing, China
- 10Shanghai Institute of Infectious Disease and Biosafety, Shanghai, China
- ↵†Correspondence: zhangshuo001{at}163.com (S. Zhang); huyl{at}sinovac.com (Y.L. Hu.); dongxp238{at}sina.com(X.P. Dong)
↵* These authors contributed equally to this work.
Posted December 31, 2022.
Safety and Effectiveness of SA58 Nasal Spray against COVID-19 Infection in Medical Personnel:An Open-label, Blank-controlled Study
